HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
HOPE Therapeutics (NASDAQ: NRXP) announced a strategic acquisition of a stake in Cohen and Associates, LLC and the addition of Rebecca Cohen, MD as HOPE Medical Director on October 20, 2025. Cohen and Associates brings over a decade of interventional psychiatry and TMS expertise and offers ketamine, TMS, and medication management for suicidal depression, PTSD and other CNS disorders.
The company said the deal enables immediate expansion in Western Florida and Palm Beach and is expected to be accretive to HOPE Therapeutics revenue and EBITDA, while Dr. Cohen will oversee medical standards across HOPE’s Florida locations.
HOPE Therapeutics (NASDAQ: NRXP) ha annunciato un'acquisizione strategica di una partecipazione in Cohen and Associates, LLC e l'aggiunta di Rebecca Cohen, MD come Direttrice Medica di HOPE il 20 ottobre 2025. Cohen and Associates porta oltre un decennio di psichiatria interventistica e TMS e offre ketamina, TMS e gestione farmacologica per depressione suicidaria, PTSD e altri disturbi CNS.
La società ha dichiarato che l'accordo consente un'espansione immediata nella Florida occidentale e a Palm Beach ed è previsto che sia incrementale ai ricavi e all'EBITDA di HOPE Therapeutics, mentre il Dr. Cohen supervisionerà gli standard medici presso le sedi HOPE in Florida.
HOPE Therapeutics (NASDAQ: NRXP) anunció una adquisición estratégica de una participación en Cohen and Associates, LLC y la incorporación de Rebecca Cohen, MD como Directora Médica de HOPE el 20 de octubre de 2025. Cohen and Associates aporta más de una década de experiencia en psiquiatría intervencionista y TMS, y ofrece ketamina, TMS y manejo de medicamentos para la depresión suicida, TEPT y otros trastornos del SNC.
La empresa dijo que el acuerdo permite una expansión inmediata en el oeste de Florida y en Palm Beach y se espera que contribuya al crecimiento de los ingresos y al EBITDA de HOPE Therapeutics, mientras la Dra. Cohen supervisará los estándares médicos en las ubicaciones de HOPE en Florida.
HOPE Therapeutics (NASDAQ: NRXP)은 Cohen and Associates, LLC의 지분에 대한 전략적 인수와 2025년 10월 20일 HOPE 의학 이사로 Rebecca Cohen, MD를 추가했다고 발표했다. Cohen and Associates는 10년이 넘는 중재 정신의학 및 TMS 전문지식을 보유하고 있으며, 자살적 우울증, PTSD 및 기타 중추신경계 질환에 대해 케타민, TMS 및 약물 관리 서비스를 제공한다.
이 거래는 플로리다 서부와 팜비치에서 즉시 확장을 가능하게 하며, HOPE Therapeutics의 매출 및 EBITDA에 실질적으로 기여할 것으로 예상되며, Cohen 박사는 플로리다 내 HOPE 지사들의 의료 표준을 감독할 것이다.
HOPE Therapeutics (NASDAQ: NRXP) a annoncé une acquisition stratégique d'une participation dans Cohen and Associates, LLC et l'ajout de Rebecca Cohen, MD au poste de Directrice médicale de HOPE le 20 octobre 2025. Cohen and Associates apporte plus d'une décennie d'expertise en psychiatrie interventionnelle et TMS, et propose de la kétamine, du TMS et de la gestion médicamenteuse pour la dépression suicidaire, le PTSD et d'autres troubles du SNC.
La société a déclaré que l'opération permet une expansion immédiate dans l'ouest de la Floride et à Palm Beach et qu'elle devrait être favorable aux revenus et à l'EBITDA de HOPE Therapeutics, tandis que le Dr Cohen supervisera les normes médicales dans les sites HOPE en Floride.
HOPE Therapeutics (NASDAQ: NRXP) gab eine strategische Übernahme einer Beteiligung an Cohen and Associates, LLC bekannt und die Einstellung von Rebecca Cohen, MD als Medizinische Direktorin von HOPE am 20. Oktober 2025. Cohen and Associates bringt über ein Jahrzehnt Erfahrung in interventioneller Psychiatrie und TMS mit und bietet Ketamin, TMS und Medikamentenmanagement für suizidale Depressionen, PTSD und andere ZNS-Störungen.
Das Unternehmen sagte, dass die Vereinbarung eine sofortige Expansion in West-Florida und Palm Beach ermögliche und voraussichtlich zu Umsatz- und EBITDA-Wachstum von HOPE Therapeutics beitragen wird, während Dr. Cohen die medizinischen Standards an HOPE-Standorten in Florida überwachen wird.
HOPE Therapeutics (NASDAQ: NRXP) أعلنت عن صفقة استحواذ استراتيجية على حصة في Cohen and Associates, LLC وإضافة Rebecca Cohen, MD ك مديرة طبية لـ HOPE في 20 أكتوبر 2025. يجلب Cohen and Associates أكثر من عقد من الخبرة في الطب النفسي التدخلي وTMS ويقدم الكيتامين وTMS وإدارة الأدوية للاكتئاب الانتحاري، واضطراب ما بعد الصدمة وغيرها من اضطرابات الجهاز العصبي المركزي.
وقالت الشركة إن الصفقة تتيح توسيعاً فوريّاً في غرب فلوريدا وفلوريدا بالم بيتش ومن المتوقع أن تكون مساهمة في إيراداتHOPE Therapeutics و EBITDA، بينما ستشرف الدكتورة كوهين على المعايير الطبية في مواقع HOPE في فلوريدا.
HOPE Therapeutics（纳斯达克股票代码：NRXP）宣布在 Cohen and Associates, LLC 的股份的战略收购及任命 Rebecca Cohen, MD 为 HOPE 首席医疗总监，日期为 2025 年 10 月 20 日。Cohen and Associates 拥有十余年的介入精神病学与 TMS 专业知识，提供用于自杀性抑郁、创伤后应激障碍（PTSD）及其他中枢神经系统疾病的氯胺酮治疗、TMS 和药物管理。
公司表示，该交易将使在西佛州和棕榈滩地区实现立即扩张，并预计将 提升 HOPE Therapeutics 的收入和 EBITDA，同时 Cohen 博士将监管佛州各 HOPE 点的医疗标准。
- Acquisition adds a premier interventional psychiatry clinic to HOPE network
- Appointment of Dr. Rebecca Cohen strengthens TMS clinical leadership
- Planned immediate expansion into Western Florida and Palm Beach
- Deal described as accretive to HOPE Therapeutics revenue and EBITDA
- Adds full suite of treatments: ketamine, TMS, medication management
- None.
Insights
HOPE adds a regional interventional psychiatry clinic and names Dr. Rebecca Cohen Medical Director, aiming rapid Florida expansion and revenue accretion.
HOPE acquired a strategic interest in Cohen and Associates, LLC and appointed Dr. Rebecca Cohen as Medical Director, integrating a practice that offers ketamine, TMS and medication management into the HOPE Network. This transaction creates an immediate operational foothold in Western Florida and Palm Beach and pairs clinical leadership with existing anesthesia and pain-management capabilities within HOPE.
The main dependencies are execution of the planned rapid expansion and clinical standardization under Dr. Cohen’s oversight; the release states the acquisition is expected to be accretive to HOPE Therapeutics’ revenue and EBITDA but provides no financial details. Risks include integration challenges, variability in procedure volumes, and the need to maintain consistent care pathways across sites.
Watch for concrete milestones over the next 6–18 months: rollout timing for the Western Florida and Palm Beach locations, any disclosed revenue or EBITDA figures, and metrics on patient throughput or TMS/ketamine utilization that would validate the accretion claim; the announcement date is
- Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS)
- Dr. Rebecca Cohen has joined HOPE as Medical Director
- Immediate expansion is planned in Western Florida and Palm Beach
- Acquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA
MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), today announced the acquisition of a strategic interest in Cohen and Associates, LLC (“Cohen, LLC”) and its incorporation into the HOPE Network. Additionally, Rebecca Cohen, MD has joined HOPE as Medical Director, overseeing medical standards of care throughout HOPE’s Florida locations.
Cohen, LLC is one of the premier interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Transcranial Magnetic Stimulation (“TMS”), and medication management.
Dr. Cohen is an Interventional Psychiatrist and Psychopharmacologist specializing in the treatment of mood and anxiety disorders as well as a nationally recognized expert in TMS. She founded her practice in 2014 as one of the first dedicated interventional psychiatry practices in the United States. Her academic background spans Tufts University, Boston University, where she was recipient of the psychiatry department’s Malamud Award for Excellence, and Georgetown University. Dr Cohen has been honored as a Fellow of both the American Psychiatric Association and the International Clinical TMS Society.
“We are excited to launch HOPE Therapeutics in Florida with Dr. Cohen’s passionate medical leadership. Her background and training perfectly complement the anesthesia and pain management expertise brought by Stephen Durand, RN, founder of Dura Medical, now a key component of HOPE. Rebecca dedicated her practice to TMS and other neuroplastic therapies when the field was in its infancy and has continued to advance the science of interventional psychiatry. Her extraordinary compassion for patients fits perfectly with our culture of bringing HOPE to life,” said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics.
“I am thrilled to be assuming a leadership role in HOPE Therapeutics at a moment when TMS is demonstrating dramatic results for patients with potential to heal depression in weeks, rather than months. Together with HOPE’s leadership, we aim to remain on the cutting edge of life transforming therapy for depression and PTSD and to rapidly expand to change the lives of the 13 million Americans who tragically contemplate suicide each year,” said Dr. Cohen.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently re-filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
mduffy@nrxpharma.com
Brian Korb
Managing Partner, astr Partners
(917) 653-5122
brian.korb@astrpartners.com
FAQ
What did HOPE Therapeutics announce on October 20, 2025 about NRXP?
How will the Cohen and Associates acquisition affect HOPE Therapeutics' operations?
Does HOPE say the transaction impacts revenue or EBITDA for NRXP?
What clinical services does Cohen and Associates bring to the HOPE Network?
Who is Dr. Rebecca Cohen and what role will she play at HOPE Therapeutics (NRXP)?
